Table 1.
Clinical and Serological Characteristics of COVID-19 Patients versus Controls.
| COVID-19 (n=22) | Controls (n=28) | p-Value | |
|---|---|---|---|
| Age, median years (IQR) | 76 (16) | 57 (50) | <0.001** |
| Sex, male, N (%) | 11 (50) | 13 (46) | 0.513 |
| BMI, median (IQR) | 29 (10) | 27 (4) | 0.336 |
| Hospitalization time, median (days) | 9 (12) | 9 (9) | 0.958 |
| Number of SARS-CoV-2 positive patients, as determined by CT Value (%) | 12 (55) | n/a | n/a |
| Immunosuppressive therapy, N (%) | 2 (9) | 4 (14) | 0.018* |
| Steroid therapy, N (%) | 7 (32) | 5 (18) | 0.041* |
| High dose dexamethasone (0.4-0.8mg/kg/day) | 1 (5) | 0 (0) | 0.440 |
| Anticoagulation therapy, N (%) | 16 (73) | 11 (39) | 0.009** |
| CRP, mg/L, median (IQR) | 191 (182) | 74 (136) | 0.010** |
| LDH, U/L, median (IQR) | 444 (441) | 280 (251.5) | 0.032* |
| INR, median (IQR) | 1.3 (1.1) | 1.1 (0.1) | 0.150 |
| Thrombocytes, 109/L, median (IQR) | 171.0 (291.0) | 281.0 (174.0) | 0.145 |
| Leucocytes, 109/L, median (IQR) | 11.1 (16.6) | 9.3 (5.3) | 0.773 |
| Neutrophilic granulocytes, 109/L, median (IQR) | 7.3 (12.9) | 5.0 (10.4) | 0.232 |
| Lymphocytes, 109/L, median (IQR) | 0.6 (0.5) | 1.5 (2.0) | 0.018* |
| Monocytes, 109/L, median (IQR) | 0.4 (0.7) | 0.5 (0.6) | 0.307 |
*significant at the 0.05 level, ** significant at the 0.01 level.
Bold means significant values.